Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.
Peripheral blood eosinophil counts and serum levels and in vitro production of eosinophilopoietic cytokines were assessed before and at frequent intervals after diethylcarbamazine treatment of Bancroftian filariasis. Eosinophil counts peaked at day 7 after the start of treatment (359% +/- 118% of pretreatment levels) and declined to pretreatment levels by day 17. Serum interleukin (IL)-5, undetectable in 14 of 15 patients before treatment, rose sharply but transiently, with peak levels (32 +/- 7 pg/mL) 2 days after diethylcarbamazine treatment. Granulocyte-macrophage colony-stimulating factor and IL-3 were not detectable in serum at any time. In vitro mitogen-induced IL-5 levels decreased significantly in 7 of 9 patients 3 days after treatment when serum IL-5 was at near-peak levels. By day 10 IL-5 values increased in 8 of 9 patients compared with treatment values (P < .02). These data define the temporal relation between serum IL-5 levels and the subsequent development of eosinophilia and suggest that lymphocytes are the source of IL-5.
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
A P
AP
Limaye
E A
EA
Ottesen
V
V
Kumaraswami
J S
JS
Abrams
J
J
Regunathan
V
V
Vijayasekaran
K
K
Jayaraman
T B
TB
Nutman
D000293:Adolescent; D000328:Adult; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004605:Elephantiasis, Filarial / Q000188:drug therapy / Q000276:immunology*; D004802:Eosinophilia / Q000276:immunology*; D004804:Eosinophils / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000097:blood* / Q000378:metabolism; D015759:Ionomycin / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D015848:Interleukin-5; D015759:Ionomycin; D013755:Tetradecanoylphorbol Acetate; D004049:Diethylcarbamazine